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Introduction
The promise of pharmacogenomics testing, to find the right medication at the right dose for 
the right patient at the right time, sits at the heart of precision medicine. Identifying genetic 
variants that contribute to inter-patient variability in drug disposition and effect allows 
clinicians to select a more appropriate medication for a patient’s condition by limiting 
adverse drug events and maximizing beneficial effects. However, as pharmacogenomics is 
increasingly integrated into prevention-based healthcare, a major obstacle to effective 
implementation of pharmacogenomics testing is the lack of adequate knowledge of 
healthcare providers on interpretation of these test results [1, 2].
A second barrier to effective implementation of pharmacogenomics testing is the cost 
associated with testing, which is not universally covered on a preventative basis. 
Comprehensive, multigene panels are more cost-effective than multiple instances of single-
gene targeted testing over a patient’s lifetime [3] and give providers an opportunity to assess 
the risk of adverse drug reactions for a patient’s current and future medications. 
Pharmacogenetic testing is not routinely covered by insurance without prior authorization. 
The testing discussed in each of the following clinical vignettes was provided free to each 
patient. This pharmacogenetic testing is funded through multiple initiatives including a 
pragmatic clinical trial. Outside of these initiatives, the cost of pharmacogenetic testing 
varies widely depending on payer coverage and university subsidies.
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Clinicians understand that patients respond differently to identical treatments. Family history 
has long served as a source of genetic information. To provide some background, both drug-
gene and drug-drug interactions (DDIs) may contribute to this variability. Drug-gene 
interactions often result from genetic variability in drug disposition enzymes. The major 
drug metabolizing enzymes are those that belong to the cytochrome P450 (CYP) 
superfamily, which accounts for the metabolism of 70–80% of clinically-used medications 
[4]. Genetic variants in genes coding for these CYP enzymes can alter enzyme function 
causing decreased or increased plasma concentrations of medication and lead to loss of 
beneficial effect or increase the risk for adverse effects.
To assist with interpretation of test results, the Clinical Pharmacogenetics Implementation 
Consortium (CPIC®) (https://cpicpgx.org/) and the Dutch Pharmacogenetics Working 
Group (DPWG) provide guidelines, with dosing recommendations for clinically actionable 
pharmacogenetic (genetic variants in one or few genes as opposed to the entire genome) test 
results. Refer to Supplemental Table 1: Comparison of the Clinical Pharmacogenetics 
Implementation Consortium (CPIC®) and the Dutch Pharmacogenetics Working Group 
(DPWG). (Note to printer: put this Supplemental Table 1 online only.). The predicted 
phenotypes are classified as poor, intermediate/reduced, extensive, rapid, or ultra-rapid and 
can be deduced from the presence of genetic variants (alternative alleles). This predicted 
phenotype is the individual’s “metabolizer status.” The guidelines use an asterisk-based 
nomenclature, where *1 is often the reference allele and assigned based on an individual 
lacking the alternative allele. The reference allele is (typically) used to refer to “normal” (not 
increased, decreased or altered) function of the drug metabolizing enzyme.
Many prescribed medications are substrates, inhibitors, and inducers of CYP enzymes. 
Substrates bind (interact) to CYP enzymes and are converted into active or inactive forms 
(metabolites). Sometimes, the administered medication is an inactive prodrug, which 
requires conversion to active form by the CYP system to convey its therapeutic effect. 
Inhibitors are medicines/compounds that decrease the function of the CYP enzyme, while 
inducers increase the function (Table 1). A list of common CYP substrates, inhibitors, and 
inducers are listed at http://medicine.iupui.edu/clinpharm/ddis/main-table/. Certain 
medicines can be categorized as having more than one effect (e.g. fluoxetine is a substrate 
and inhibitor).
As pharmacogenomics knowledge accumulates [5], healthcare institutions have 
implemented genotype-guided therapy in clinical practice. For example, the Indiana 
Genomics Implementation: An Opportunity for the Underserved (INGENIOUS) Trial [6–8] 
is currently underway at two major healthcare institutions: a safety net health system and a 
major university health system. Individuals that receive a first prescription, for one of the 
medications (with known guidelines regarding pharmacogenetic testing), were identified 
electronically as being trial eligible. They were contacted to enroll and after consenting, they 
were either randomized to the non-genotyping arm or randomized to the genotyping arm and 
tested.
Although the benefit of pharmacogenetic testing would be most significant if all patients are 
tested using a multigene panel prior to prescription of medications, this is challenging in the 
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situation where testing is costly and not covered by insurance. In such a setting, healthcare 
providers need to be able to assess which individuals would benefit from pharmacogenetic 
testing instead of testing all individuals or individuals based on receiving a prescription for a 
particular medication. Being able to identify those patients who would benefit the most from 
testing due to concerns about inefficacy or toxicity is particularly important in resource-
constrained environments. The INGENIOUS trial involves healthcare providers, including 
advanced practice nurses (APNs), who provide primary and specialty care, requiring these 
providers to interpret test results. APNs are perfectly positioned in both settings to apply test 
results within the clinical context. By becoming familiar with these results, the lack of 
knowledge among clinicians can slowly be overcome [1, 9, 10].
The aims of this paper are to demonstrate (1) the benefit of pharmacogenetic testing and (2) 
the aspects involved with interpretation and application of results in a case-based manner. 
The three clinical vignettes below exemplify the benefits and complexities of 
pharmacogenetic-guided therapy in clinical practice. Table 2 includes a synopsis of the 
pertinent drug-gene and DDIs discussed in these clinical vignettes. A copy of a sample de-
identified pharmacogenetics report can be found in the supplement material at https://
ascpt.onlinelibrary.wiley.com/doi/abs/10.1002/cpt.347
Vignettes
The vignette illustrates how pharmacogenetic testing can be used as rationale for caregivers 
and payers to provide coverage for a necessary alternative medication to benefit a medically 
underserved person. Clopidogrel is used to inhibit platelet activation following PCI. It is a 
prodrug that is converted to an active metabolite (activated) by CYP2C19 in the liver. 
Compared to clopidogrel, the contribution of CYP2C19 in metabolism of ticagrelor and 
prasugrel is minor and, therefore, exposure to ticagrelor and prasugrel is influenced less by 
genetic variation in CYP2C19.
Ticagrelor and prasugrel are more expensive than clopidogrel. Some payers may be reluctant 
to reimburse the cost of these clopidogrel alternatives as first line therapy. When provided 
genetic information as justification, the insurer approved the use of ticagrelor in this 
situation.
Several studies have evaluated the efficacy of genotype-guided selection of antiplatelet 
therapies [12, 13]. Cost-effectiveness simulations tend to compare three scenarios: (1) 
universal clopidogrel use, (2) universal ticagrelor use, and (3) genotype-guided selection 
[12]. Although payers prioritize findings from randomized controlled trials ahead of 
retrospective studies [14], the potential cost of rehospitalization due to adverse events 
provides incentive to act on genetic information.
The tricyclic antidepressant (TCA), amitriptyline, is often prescribed for depression, anxiety, 
obsessive-compulsive and bipolar disorders, and neuropathic pain at doses starting at 10 mg 
to a maximum of 300 mg daily. For migraine and headache prevention, 10 mg amitriptyline 
is initially prescribed with the goal of increasing doses to 25 or 30 mg daily [15]. In this 
case, amitriptyline was prescribed for refractory left temporal headaches instead of NSAIDs 
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because of a likely DDI with warfarin that could result in bleeding and gastric mucosal 
damage [16]. Amitriptyline is mainly metabolized by CYP2C19 to nortriptyline that is also 
pharmacologically active, while CYP2D6 is responsible for metabolism of both 
amitriptyline and nortriptyline to less active hydroxy-metabolites (i.e. hydroxyamitriptyline 
and hydroxynortriptyline) [17]. Genotype-informed recommendations consider genetic 
variants in both CYP2C19 and CYP2D6 because CYP2C19 activity impacts the ratio of 
amitriptyline to nortriptyline while CYP2D6 has a larger influence on overall drug 
clearance. Her reduced CYP2D6 activity in addition to further inhibition of CYP2D6 by 
diphenhydramine or escitalopram could, in combination with a dose escalation to 30 mg 
daily, put her at risk of toxicity [18].
Warfarin, a widely prescribed anticoagulant, functions by inhibiting the activity of 
VKORC1, a major component of the vitamin K-dependent prothrombin clotting pathway. 
Too little inhibition of VKORC1 places the patient at risk of thrombosis, and too much 
inhibition increases the risk of major bleeding events. Consequently, warfarin has a narrow 
therapeutic window that requires regular monitoring of the patient’s International 
Normalized Ratio (INR) of prothrombin time (PT).
Common genetic variants in VKORC1 alter a patient’s sensitivity to warfarin resulting in 
patients that are more sensitive to warfarin and require a lower dose to achieve therapeutic 
targets. CYP4F2 acts as a counterpart to VKORC1 by removing vitamin K from the vitamin 
K pathway and limiting excessive accumulation of vitamin K. Although genetic alterations 
in CYP4F2 are associated with warfarin dose changes, the influence is smaller than that of 
variants in VKORC1 [19]. The principal route of metabolism for S-warfarin occurs through 
CYP2C9, while R-warfarin is metabolized by CYP3A4 with minor contribution from 
CYP2C8, CYP1A1, CYP1A2, CYP2C18, and CYP2C19. Since S-warfarin is the more 
potent inhibitor of the vitamin K epoxide reductase complex, genetic variants of CYP2C9 
result in reduced metabolism of S-warfarin and increased risk of over-anticoagulation (i.e. 
bleeding events).
The vignette demonstrates the accuracy of genotype-guided warfarin dosing strategies. The 
patient presented with an existing prescription for a warfarin maintenance dose that was 
empirically (without genetic testing) determined. Genotype-guided dosing incorporates the 
patient’s genotype (according to www.WarfarinDosing.org) and warrants a maintenance 
dose of 1.8 mg per day, or approximately 36% of the normal dose of 5 mg. In this case, the 
patient was titrated appropriately to alternating doses of 1–2 mg daily. Had the patient 
received pharmacogenetic testing prior to her initial warfarin prescription, it is possible her 
time to a therapeutic INR would have been reduced.
Pharmacogenetic testing is expected to improve efficacy in patients with depression, who 
typically respond to their first treatment only half of the time [20, 21]. CYP2D6 and 
CYP2C19 are responsible for metabolizing TCAs, most SSRIs, and half of all 
antipsychotics. Testing improves responder rates and tolerability [21] and may decrease the 
number of reported adverse events while increasing overall functioning [20].Venlafaxine is a 
SNRI that is well-absorbed in the intestines and extensively metabolized by CYP2D6 in the 
liver, with minor involvement of CYP2C19.
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Venlafaxine requires a strict dosing regimen to maintain therapeutic concentrations. 
Approximately 80% of patients have CYP2D6 variants, resulting in increased or decreased 
CYP2D6 activity [2]. DPWG guidelines for individuals with reduced activity of CYP2D6 
recommend the selection of an alternative medicine not metabolized by CYP2D6 [22]. 
Therefore, the prescriber in the third vignette discontinued venlafaxine and prescribed an 
alternative not metabolized by CYP2D6.
Conclusion
Available pharmacogenetic testing can already benefit individual patients; however, APNs 
and other providers experience significant challenges when implementing such testing. As 
more pharmacogenetic or pharmacogenomic studies are performed, the data and evidence 
are evolving rapidly. Providers are encouraged to make treatment decisions based on the 
highest quality evidence at the time and not use pharmacogenetic testing when the benefit is 
not known.
Efforts are currently underway to harmonize CPIC and DPWG guidelines, but providers 
should note that differences exist. In addition to providing a straightforward example of 
pharmacogenetic implementation, the third clinical vignette illustrates a notable difference 
between CPIC and DPWG guidelines. Currently no primary evidence exists linking altered 
metabolism of venlafaxine to CYP2D6 variants, therefore, CPIC has not issued any 
guidelines for this drug-gene combination. DPWG, in contrast, provides guidelines based on 
drug-gene interactions of existing medications, which associates variants resulting in less 
active CYP2D6 with decreased efficacy of venlafaxine. It is well-established that CYP2D6 
is the most variable member of the CYPs and studies demonstrate altered drug metabolism 
due to CYP2D6 variants. This facilitates DPWG to extend general guidelines for other 
medicines metabolized by CYP2D6 to venlafaxine.
Reimbursement for pharmacogenetic testing, using single-gene tests, generally occurs under 
a reactive ordering approach, meaning that a patient is tested before a high-risk prescription 
or in response to adverse events [14]. The INGENIOUS study broadens the cost-
effectiveness and impact of reactive testing by using the same multigene panel for all 
patients enrolled in the study, regardless of the medication that prompted enrollment. 
Because of the wide inclusion criteria, patients often present with multiple current 
medications and comorbidities. Given the frequency of actionable genetic variants, the 
multigene panel approach routinely identifies findings unrelated to the medication which 
prompted the trial team to contact the patient regarding enrollment. These findings may 
include actionable genetic variants for medications the patient is not currently taking yet 
might be prescribed in the future. Other times drug-gene interactions are relevant to current 
medications.
Every patient presents a unique challenge to the pharmacogenetic interpretation of his or her 
case. This makes it difficult to automate interpretation of test results and requires a 
knowledgeable provider to assess each patient’s genotype and medications. In these clinical 
vignettes, we presented examples of pharmacogenetic testing that required nuanced 
interpretation of drug-gene and DDIs. Pharmacogenetic test interpretation should not be 
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confined to the medication of interest; it is also necessary to assess drug-gene interactions of 
existing medications to explain symptoms, inform selection of alternative treatment options, 
and improve efficacy of the patient’s medication profile. With sufficient knowledge and 
experience, APNs will become more confident in applying pharmacogenetic results within 
the clinical context.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
Funding: The INGENIOUS trial (NCT02297126) is sponsored by an NIH/NHGRIU01-grant (HG007762). BTG is 
supported by the NIH-U01 HG007762 and by the Indiana Clinical and Translational Sciences Institute Young 
Investigator Award [Grant UL1 TR001108]. MTE was supported by an NIH/NIDDK award (K08DK107864). This 
project was also supported by an NIH/NIGMS award entitled the Indiana University Comprehensive Training in 
Clinical Pharmacology (T32GM008425) which provided stipend support for CRF and SNL. MS was supported by 
the Vera Bradley Foundation for Breast Cancer
References
1. Bousman CA, Jaksa P, and Pantelis C, Systematic evaluation of commercial pharmacogenetic 
testing in psychiatry: a focus on CYP2D6 and CYP2C19 allele coverage and results reporting. 
Pharmacogenet Genomics, 2017 27(11): p. 387–393. [PubMed: 28777243] 
2. Ji Y, et al., Preemptive Pharmacogenomic Testing for Precision Medicine: A Comprehensive 
Analysis of Five Actionable Pharmacogenomic Genes Using Next-Generation DNA Sequencing 
and a Customized CYP2D6 Genotyping Cascade. J Mol Diagn, 2016 18(3): p. 438–445. [PubMed: 
26947514] 
3. Van Driest SL, et al., Clinically actionable genotypes among 10,000 patients with preemptive 
pharmacogenomic testing. Clin Pharmacol Ther, 2014 95(4): p. 423–31. [PubMed: 24253661] 
4. Zanger UM and Schwab M, Cytochrome P450 enzymes in drug metabolism: regulation of gene 
expression, enzyme activities, and impact of genetic variation. Pharmacol Ther, 2013 138(1): p. 
103–41. [PubMed: 23333322] 
5. Peterson JF, et al., Attitudes of clinicians following large-scale pharmacogenomics implementation. 
Pharmacogenomics J, 2016 16(4): p. 393–8. [PubMed: 26261062] 
6. Skaar TC, INdiana GENomics Implementation Opportunity for the UnderServed. 2017.
7. Eadon MT, et al., Implementation of a pharmacogenomics consult service to support the 
INGENIOUS trial. Clin Pharmacol Ther, 2016 100(1): p. 63–6. [PubMed: 26850569] 
8. Rosenman MB, et al., Lessons Learned When Introducing Pharmacogenomic Panel Testing into 
Clinical Practice. Value in Health, 2017 20(1): p. 54–59. [PubMed: 28212969] 
9. Chase DA, Baron S, and Ash JS, Clinical Decision Support and Primary Care Acceptance of 
Genomic Medicine. Stud Health Technol Inform, 2017 245: p. 700–703. [PubMed: 29295188] 
10. Empey PE, et al., Multisite Investigation of Strategies for the Implementation of CYP2C19 
Genotype-Guided Antiplatelet Therapy. Clin Pharmacol Ther, 2017.
11. Huang B, et al., Effect of cytochrome P450 2C19*17 allelic variant on cardiovascular and 
cerebrovascular outcomes in clopidogrel-treated patients: A systematic review and meta-analysis. J 
Res Med Sci, 2017 22: p. 109. [PubMed: 29026425] 
12. Borse MS, et al., CYP2C19-guided antiplatelet therapy: a cost-effectiveness analysis of 30-day and 
1-year outcomes following percutaneous coronary intervention. Pharmacogenomics, 2017 18(12): 
p. 1155–1166. [PubMed: 28745582] 
13. Bhopalwala A, et al., Routine Screening for CYP2C19 Polymorphisms for Patients being Treated 
with Clopidogrel is not Recommended. Hawaii J Med Public Health, 2015 74(1): p. 16–20.
Fulton et al. Page 6
J Nurse Pract. Author manuscript; available in PMC 2019 November 02.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
14. Keeling NJ, et al., Preemptive pharmacogenetic testing: exploring the knowledge and perspectives 
of US payers. Genet Med, 2017.
15. Lexicomp. Amitriptyline: Drug information. 2018.
16. Vranckx P, Valgimigli M, and Heidbuchel H, The Significance of Drug-Drug and Drug-Food 
Interactions of Oral Anticoagulation. Arrhythm Electrophysiol Rev, 2018 7(1): p. 55–61. 
[PubMed: 29636974] 
17. Atasayar G, et al., Association of MDR1, CYP2D6, and CYP2C19 gene polymorphisms with 
prophylactic migraine treatment response. J Neurol Sci, 2016 366: p. 149–154. [PubMed: 
27288795] 
18. Hicks JK, et al., Clinical pharmacogenetics implementation consortium guideline (CPIC) for 
CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin 
Pharmacol Ther, 2016.
19. Shahabi P, et al., An expanded pharmacogenomics warfarin dosing table with utility in generalised 
dosing guidance. Thromb Haemost, 2016 116(2): p. 337–48. [PubMed: 27121899] 
20. Herbert D, et al., Genetic testing as a supporting tool in prescribing psychiatric medication: Design 
and protocol of the IMPACT study. J Psychiatr Res, 2017 96.
21. Perez V, et al., Efficacy of prospective pharmacogenetic testing in the treatment of major 
depressive disorder: results of a randomized, double-blind clinical trial. BMC Psychiatry, 2017 
17(1): p. 250. [PubMed: 28705252] 
22. Nassan M, et al., Pharmacokinetic Pharmacogenetic Prescribing Guidelines for Antidepressants: A 
Template for Psychiatric Precision Medicine. Mayo Clin Proc, 2016 91(7): p. 897–907. [PubMed: 
27289413] 
23. Lee YM, et al., Assessment of patient perceptions of genomic testing to inform pharmacogenomic 
implementation. Pharmacogenet Genomics, 2017 27(5): p. 179–189. [PubMed: 28267054] 
24. Winner J, et al., Psychiatric pharmacogenomics predicts health resource utilization of outpatients 
with anxiety and depression. Transl Psychiatry, 2013 3: p. e242. [PubMed: 23511609] 
25. Hicks JK, et al., Patient Decisions to Receive Secondary Pharmacogenomic Findings and 
Development of a Multidisciplinary Practice Model to Integrate Results Into Patient Care. Clin 
Transl Sci, 2018 11(1): p. 71–76. [PubMed: 28749586] 
26. Bank PCD, et al., Comparison of the Guidelines of the Clinical Pharmacogenetics Implementation 
Consortium and the Dutch Pharmacogenetics Working Group. Clin Pharmacol Ther, 2018 103(4): 
p. 599–618. [PubMed: 28994452] 
Fulton et al. Page 7
J Nurse Pract. Author manuscript; available in PMC 2019 November 02.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Highlights
1. APNs are crucial for the effective implementation of precision medicine
2. Drug-gene and drug-drug interactions present patient-specific challenges
3. Two sets of guidelines assist with interpretation and patient recommendations
4. With sufficient knowledge and experience, APNs can apply pharmacogenetic 
results
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Clinical vignette 1: clopidogrel
A 50-year-old Hispanic man presented to the emergency department with chest pain 
radiating to the left arm, diaphoresis, and shortness of breath. An electrocardiogram 
demonstrated anterior ST elevation myocardial infarction (STEMI) with significant 3-
vessel coronary artery disease. He underwent percutaneous coronary intervention (PCI) 
and placement of a bare metal stent. He was started on the anticoagulant, ticagrelor, 90 
mg twice daily plus aspirin (324 mg and then 81 mg daily). His lack of health insurance 
coverage necessitated that he be switched to clopidogrel a month later because the cost 
for 90 days of treatment with clopidogrel would be $8.84 while the comparable treatment 
with ticagrelor would be $175.97.
The order for clopidogrel prompted patient contact to enroll in the trial, randomization to 
the genotyping arm and pharmacogenetic testing. The patient’s test result revealed he has 
the CYP2C19 *17/*17 genotype. Clopidogrel is converted to active form by CYP2C19. 
Having two gain of function alleles (*17) predicts that he has increased CYP2C19 
metabolic activity. As a result, he is at higher risk of bleeding when prescribed 
clopidogrel [11].
Following discussion with his health insurance providers and care team, the patient was 
maintained on treatment with ticagrelor plus aspirin. He reported no chest pain, no 
significant fatigue after walking, absence of diaphoresis, and no symptoms or signs of 
bleeding at his 1-month follow-up visit. For this patient, pharmacogenetic testing 
provided support for treatment based on both his clinical and genetic factors.
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Clinical vignette 2: amitriptyline and warfarin
A 66-year-old White woman with a history of hypertension, restless legs syndrome, and 
fibromyalgia received a prescription for amitriptyline for refractory left temporal 
headaches. This medication order prompted the trial team to contact the patient regarding 
enrollment, which resulted in pharmacogenetic testing. She has a history of two separate 
episodes of a pulmonary embolus and deep venous thrombosis for which she is on life-
long anticoagulation with warfarin.
For her headaches, she was initially prescribed 10 mg amitriptyline at night with a goal 
dose of 30 mg. Additional medications included; 50 mg diphenhydramine daily, 10 mg 
escitalopram daily, and alternating doses of 1 mg and 2 mg warfarin daily.
Pharmacogenetic testing revealed the following genotypes: CYP2C19 *1/*1, CYP2D6 
*4/*41, CYP2C9 *2/*3, VKORC1 rs9923231 (c.−1639G>A) A/A, and CYP4F2 *1/*3. 
Amitriptyline is metabolized by CYP2C19 and CYP2D6. Although the patient has 
normal CYP2C19 metabolic activity, she has reduced CYP2D6 metabolic activity, which 
will decrease her ability to metabolize amitriptyline. She also has a DDI, as both 
diphenhydramine and escitalopram further inhibit her CYP2D6 activity. Both the drug-
gene and DDIs are expected to lead to higher than expected levels of amitriptyline. Based 
on these factors, she was at higher risk for developing adverse events on amitriptyline. 
The initial therapy of 10 mg was likely too low to precipitate an adverse event, but 30 mg 
nightly increases her risk and requires monitoring. Although her headaches improved 
during amitriptyline therapy, she was concerned about side effects and discontinued 
treatment.
Genetic variants in CYP2C9, VKORC1, and CYP4F2 contribute to warfarin dosing. Both 
her VKORC1 and CYP2C9 genotypes are associated with significantly increased 
sensitivity to warfarin. These genotypes explain the low maintenance dose (1–2 mg daily) 
required for her to maintain a therapeutic INR. Technically, her CYP4F2 *1/*3 genotype 
would counterbalance the predicted effects of her VKORC1 and CYP2C9 genotypes, 
suggesting an increase in warfarin dose. However, the contribution of CYP4F2 genotype 
to the variance in stable warfarin dose among patients of European ancestry is less than 
(~10%) that of VKORC1 (~30%) and CYP2C9 (~20%). The FDA drug label for warfarin 
recommends dose reduction to below 2 mg daily in individuals with this CYP2C9 and 
VKORC1 genotype combination.
In retrospect, genotype-guided recommendations support her present dose of 
anticoagulant and have potentially improved the management of her restless legs 
syndrome and headaches. Warfarin maintenance treatment is ongoing by alternating 
between 1 mg and 2 mg daily while the patient is preparing for possible total right knee 
replacement.
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Clinical vignette 3: venlafaxine
A 35-year-old White man presented to a primary clinic to establish care and treatment for 
anxiety. He reported “full blown panic attacks” which began years ago. He received 
psychiatric services and was treated with selective serotonin reuptake inhibitors (SSRIs) 
and a benzodiazepine for a short period. After a new wave of anxiety, he was prescribed 
venlafaxine, a serotonin-norepinephrine reuptake inhibitor (SNRI) at 37.5 mg daily, a low 
starting dose which is appropriate for antidepressant therapy initiation. The expected 
course of improvement in his symptoms and possible side effects of venlafaxine, 
including potential thoughts of suicide, were discussed. If the patient experienced side 
effects he was encouraged to stop taking venlafaxine immediately and notify the 
prescriber.
The prescription of venlafaxine prompted the trial team to contact the patient regarding 
enrollment, which resulted in pharmacogenetic testing. Eight days after starting 
venlafaxine, the patient contacted his healthcare provider to advise that while the 
venlafaxine seemed to help somewhat with his anxiety, he did not “feel like himself.” 
Consequently, the patient decided to stop taking venlafaxine. The provider reviewed the 
patient’s genotyping report with recommendations from the INGENIOUS adjudication 
committee, noticed his CYP2D6 genotype, attributed the side effects to his genotype, 
agreed with the patient to stop taking venlafaxine, and prescribed an alternative 
anxiolytic (clonazepam 5 mg twice daily). Two months later, he reported that his 
relationships were “better” and he is very productive at work.
Pharmacogenetic testing revealed that this patient has the CYP2D6 *4/*10 genotype 
which predicted a reduced/intermediate metabolizer status. Reduced CYP2D6 function 
will affect this patient’s ability to metabolize as many as 25% of commonly prescribed 
drugs, including antidepressants, antipsychotics, analgesics, antitussives, beta adrenergic 
blocking agents, antiarrhythmics and antiemetics [4]. Based on the patient’s CYP2D6 
metabolizer status, he has a decreased ability to metabolize venlafaxine. Knowing his 
metabolizer status explains the patient’s side effects to the medication and informed 
prescribing decisions.
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Table 1:
Glossary of terms
1. CYP: abbreviation for Cytochrome P450 enzymes which is a super family of enzymes involved in drug disposition
2. Pharmacogenomics: the study of the role of the genome (all the genes) in response to drugs/medicines. This term is often used 
interchangeably with pharmacogenetics.
2. Pharmacogenetics: usually refers to the study of how DNA variation in a single or few genes influences the response to a single drug/
medicine
4. Substrate: the compound/medicine that is acted on, through binding (interaction), with the enzyme (in this case CYP enzymes) and is 
converted into an active or inactive form (metabolite)
5. Metabolite: 1) the product formed through the interaction of a compound/medicine with an enzyme (in this case CYP enzymes) and 2) a 
substance essential for a specific metabolic process
6. Prodrug: in the administered form, the compound is pharmacologically inactive and through interaction with a CYP or other enzyme, the 
compound is activated to have therapeutic effect
7. Inhibitor: a compound/molecule/medicine that decreases the activity of an enzyme (in this case CYP enzyme)
8. Inducer: a compound/molecule/medicine that affects gene expression in a way that increases the activity of an enzyme (in this case CYP 
enzyme)
9. Allele: one of several alternative forms of the same gene, at the same place of a chromosome, which is the result of a variant in the DNA 
sequence
10. Reference allele: (typically) refers to an unaltered DNA sequence which results in not increased nor decreased (‘normal’) function of the 
drug-metabolizing enzyme
11. Genotype: an individual’s combination of two alleles
12. Phenotype: the set of observable characteristics of an individual resulting from the interaction of the individual’s genotype with the 
environment
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Table 2:
Drug-gene interactions at the time of genotype-guided dosing in three clinical vignettes
Case specific medications at 
the time of genetic testing
Relevant genotype Predicted metabolizer status Case specific recommendations based on 
drug-gene-interactions
Case #1
clopidogrel CYP2C19 *17/*17 ultra-rapid metabolizer increased risk of bleeding
Case #2
amitriptyline CYP2D6 *4/*41 reduced/intermediate metabolizer increased risk of toxicity
CYP2C19 *1/*1 normal metabolizer
escitalopram CYP2C19 *1/*1 normal metabolizer
warfarin CYP2C9 *2/*3 poor metabolizer increased risk of bleeding
VKORC1 rs9923231 A/A poor metabolizer increased sensitivity
CYP4F2 *1/*3 reduced/intermediate metabolizer
Case #3
venlafaxine CYP2D6 *4/*10 reduced/intermediate metabolizer increased risk of toxicity
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